Share Price and Basic Stock Data
Last Updated: December 9, 2025, 9:59 pm
| PEG Ratio | 2.94 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vimta Labs Ltd, operating in the medical research services sector, has reported a notable trajectory in its revenue streams. For the financial year ending March 2025, the company achieved sales of ₹344 Cr, reflecting a solid increase from ₹315 Cr in the previous year. This upward movement can be attributed to a consistent demand for its services, including testing and research, which are critical in the healthcare landscape. However, the revenue saw a dip in the quarterly results, particularly in the September 2023 quarter, where sales fell to ₹64 Cr from ₹82 Cr in the preceding quarter. Such fluctuations could be indicative of seasonality in demand or project delays. Furthermore, the trailing twelve months (TTM) sales stood at ₹365 Cr, supporting a positive outlook, although investors should remain cautious of quarterly volatility that may impact annual performance.
Profitability and Efficiency Metrics
When examining Vimta’s profitability, the company has demonstrated a commendable operating profit margin (OPM) of 35% for FY 2025, showcasing its ability to convert revenue into profit efficiently. This is a notable improvement from previous years, where OPM hovered around 30% in FY 2023. The net profit for FY 2025 stood at ₹67 Cr, an increase from ₹47 Cr in FY 2023, which translates to an earnings per share (EPS) of ₹15.13, up from ₹10.68. However, one area of concern is the decline in net profit margin to 12.88% from 15.13% the previous year, suggesting increasing expenses or pressure on pricing. The company’s efficiency metrics, including a cash conversion cycle of 235 days, appear manageable but warrant attention as extended cycles could impact liquidity. Overall, Vimta’s profitability metrics indicate a solid operational foundation, but rising costs could pose challenges ahead.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vimta Labs reflects a robust financial position, characterized by low borrowings of just ₹7 Cr against total reserves of ₹407 Cr. This translates to a debt-to-equity ratio of 0.06, indicating minimal reliance on debt financing, which is a significant strength in times of economic uncertainty. The interest coverage ratio, standing at a remarkable 42.79x, underscores the company’s ability to meet its interest obligations comfortably. Furthermore, the return on equity (ROE) at 19.4% and return on capital employed (ROCE) at 25.2% signal efficient use of shareholder funds and capital. However, the price-to-book value (P/BV) ratio of 3.08x suggests that the stock may be trading at a premium compared to its book value, which could be a potential concern for value-focused investors. Overall, Vimta’s financial ratios paint a picture of a company that is not only growing but also managing its finances prudently.
Shareholding Pattern and Investor Confidence
Vimta Labs’ shareholding structure reveals a diversified ownership model that includes 35.99% held by promoters, while foreign institutional investors (FIIs) account for 4.33%. The public holds a significant 58.80%, which is reflective of strong retail interest. The gradual decline in promoter shareholding from 37.26% in December 2022 to the current levels may raise questions regarding management confidence, but it could also indicate a strategic choice to diversify ownership. The increase in the number of shareholders, which surged to 55,933 by September 2025 from 18,916 in December 2022, highlights growing investor interest and confidence in the company’s prospects. However, the low participation from domestic institutional investors (DIIs), currently at just 0.87%, could be perceived as a risk, indicating that institutional backing remains limited, which often plays a crucial role in stock stability.
Outlook, Risks, and Final Insight
Looking ahead, Vimta Labs faces a mixed outlook marked by both opportunities and challenges. On one hand, the increasing demand for medical research services fueled by a growing healthcare sector presents significant growth potential. On the other hand, the recent fluctuations in quarterly revenues and declining profit margins could impact investor sentiment. Additionally, the company’s ability to manage rising operational costs will be crucial in maintaining its profitability. The minimal debt levels provide a cushion, but investors should monitor the cash conversion cycle closely, as delays in collections could strain liquidity. In essence, while Vimta Labs has a strong operational foundation and financial health, investors must weigh these strengths against the risks of market volatility and cost pressures, which could affect future performance and stock valuation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Vimta Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Choksi Laboratories Ltd | 79.2 Cr. | 114 | 237/60.2 | 47.7 | 35.2 | 0.00 % | 9.20 % | 6.63 % | 10.0 |
| Vimta Labs Ltd | 2,673 Cr. | 598 | 903/372 | 35.8 | 93.5 | 0.17 % | 25.2 % | 19.4 % | 2.00 |
| Industry Average | 2,673.00 Cr | 356.00 | 41.75 | 64.35 | 0.09% | 17.20% | 13.02% | 6.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 79 | 76 | 81 | 82 | 64 | 73 | 73 | 75 | 83 | 90 | 94 | 98 |
| Expenses | 55 | 54 | 55 | 57 | 58 | 48 | 50 | 47 | 49 | 54 | 57 | 61 | 64 |
| Operating Profit | 24 | 25 | 21 | 24 | 24 | 17 | 23 | 26 | 26 | 29 | 33 | 33 | 34 |
| OPM % | 30% | 32% | 27% | 29% | 29% | 26% | 31% | 36% | 35% | 35% | 37% | 35% | 35% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 0 | -1 | -1 | -1 | -1 | 5 | 2 | 2 |
| Interest | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 7 | 8 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 10 | 9 | 10 |
| Profit before tax | 17 | 18 | 14 | 16 | 16 | 8 | 13 | 16 | 17 | 19 | 28 | 25 | 25 |
| Tax % | 27% | 26% | 27% | 23% | 25% | 25% | 25% | 24% | 26% | 24% | 23% | 27% | 25% |
| Net Profit | 12 | 13 | 10 | 12 | 12 | 6 | 9 | 12 | 12 | 15 | 22 | 18 | 19 |
| EPS in Rs | 2.72 | 2.95 | 2.25 | 2.77 | 2.63 | 1.34 | 2.14 | 2.79 | 2.77 | 3.29 | 4.84 | 4.12 | 4.24 |
Last Updated: August 1, 2025, 9:25 am
Below is a detailed analysis of the quarterly data for Vimta Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 98.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 4.00 Cr..
- For Expenses, as of Jun 2025, the value is 64.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 61.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 3.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2025) to 34.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 35.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 35.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Mar 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Mar 2025) to 25.00%, marking a decrease of 2.00%.
- For Net Profit, as of Jun 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.24. The value appears strong and on an upward trend. It has increased from 4.12 (Mar 2025) to 4.24, marking an increase of 0.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: July 22, 2025, 2:45 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 127 | 116 | 138 | 154 | 183 | 213 | 181 | 209 | 276 | 315 | 289 | 344 | 365 |
| Expenses | 101 | 99 | 119 | 127 | 138 | 155 | 151 | 156 | 196 | 222 | 195 | 222 | 236 |
| Operating Profit | 26 | 17 | 19 | 27 | 45 | 58 | 30 | 53 | 80 | 94 | 94 | 122 | 129 |
| OPM % | 20% | 15% | 14% | 18% | 25% | 27% | 17% | 25% | 29% | 30% | 33% | 35% | 35% |
| Other Income | 3 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 0 | 3 | -4 | 5 | 8 |
| Interest | 2 | 1 | 1 | 2 | 5 | 5 | 4 | 2 | 2 | 3 | 2 | 2 | 2 |
| Depreciation | 9 | 11 | 10 | 10 | 16 | 20 | 21 | 23 | 23 | 31 | 33 | 35 | 37 |
| Profit before tax | 18 | 7 | 8 | 17 | 26 | 35 | 8 | 28 | 55 | 64 | 55 | 90 | 97 |
| Tax % | 25% | 24% | 23% | 36% | 36% | 28% | 17% | 25% | 26% | 26% | 25% | 25% | |
| Net Profit | 13 | 5 | 6 | 11 | 16 | 25 | 7 | 21 | 41 | 47 | 41 | 67 | 73 |
| EPS in Rs | 3.00 | 1.14 | 1.45 | 2.40 | 3.72 | 5.73 | 1.57 | 4.81 | 9.29 | 10.68 | 9.26 | 15.13 | 16.49 |
| Dividend Payout % | 33% | 44% | 34% | 0% | 27% | 17% | 0% | 21% | 11% | 9% | 11% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.54% | 20.00% | 83.33% | 45.45% | 56.25% | -72.00% | 200.00% | 95.24% | 14.63% | -12.77% | 63.41% |
| Change in YoY Net Profit Growth (%) | 0.00% | 81.54% | 63.33% | -37.88% | 10.80% | -128.25% | 272.00% | -104.76% | -80.60% | -27.40% | 76.18% |
Vimta Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 58% |
| 3 Years: | 17% |
| TTM: | 51% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 72% |
| 3 Years: | 65% |
| 1 Year: | 146% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 1:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:12 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 9 |
| Reserves | 116 | 118 | 122 | 132 | 148 | 167 | 169 | 190 | 229 | 276 | 310 | 374 | 407 |
| Borrowings | 7 | 4 | 26 | 44 | 40 | 26 | 32 | 30 | 19 | 15 | 19 | 9 | 7 |
| Other Liabilities | 22 | 21 | 23 | 42 | 40 | 40 | 39 | 49 | 54 | 65 | 61 | 79 | 95 |
| Total Liabilities | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 394 | 467 | 518 |
| Fixed Assets | 90 | 88 | 88 | 88 | 140 | 135 | 131 | 128 | 162 | 168 | 166 | 230 | 240 |
| CWIP | 2 | 0 | 6 | 53 | 0 | 4 | 2 | 17 | 0 | 12 | 59 | 38 | 55 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 0 | 0 | 0 |
| Other Assets | 57 | 58 | 82 | 80 | 92 | 99 | 105 | 122 | 138 | 174 | 170 | 198 | 224 |
| Total Assets | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 394 | 467 | 518 |
Below is a detailed analysis of the balance sheet data for Vimta Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 407.00 Cr.. The value appears strong and on an upward trend. It has increased from 374.00 Cr. (Mar 2025) to 407.00 Cr., marking an increase of 33.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 9.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 95.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.00 Cr. (Mar 2025) to 95.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 518.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 467.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 51.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 230.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 38.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 17.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 224.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 224.00 Cr., marking an increase of 26.00 Cr..
- For Total Assets, as of Sep 2025, the value is 518.00 Cr.. The value appears strong and on an upward trend. It has increased from 467.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 51.00 Cr..
Notably, the Reserves (407.00 Cr.) exceed the Borrowings (7.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 19.00 | 13.00 | -7.00 | -17.00 | 5.00 | 32.00 | -2.00 | 23.00 | 61.00 | 79.00 | 75.00 | 113.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 81 | 82 | 100 | 101 | 111 | 100 | 117 | 128 | 102 | 93 | 110 | 113 |
| Inventory Days | 175 | 158 | 213 | 183 | 209 | 199 | 191 | 140 | 154 | 195 | 260 | 210 |
| Days Payable | 87 | 66 | 77 | 184 | 148 | 115 | 114 | 139 | 108 | 124 | 87 | 88 |
| Cash Conversion Cycle | 169 | 174 | 236 | 100 | 172 | 184 | 194 | 128 | 147 | 164 | 283 | 235 |
| Working Capital Days | 65 | 109 | 99 | 22 | 62 | 78 | 64 | 89 | 87 | 78 | 98 | 96 |
| ROCE % | 16% | 6% | 7% | 11% | 17% | 21% | 6% | 14% | 24% | 24% | 20% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 330,152 | 0.1 | 14.99 | 330,152 | 2025-04-22 17:25:16 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 78 | 0.04 | 0 | 78 | 2025-04-22 17:25:16 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 18.51 | 21.77 | 18.70 | 9.68 | 3.10 |
| Diluted EPS (Rs.) | 18.24 | 21.35 | 18.32 | 9.68 | 3.10 |
| Cash EPS (Rs.) | 33.92 | 35.65 | 29.24 | 20.12 | 12.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 144.20 | 127.33 | 105.83 | 87.92 | 78.19 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 144.20 | 127.33 | 105.83 | 87.92 | 78.19 |
| Revenue From Operations / Share (Rs.) | 143.55 | 143.78 | 125.86 | 95.29 | 81.73 |
| PBDIT / Share (Rs.) | 40.96 | 44.44 | 36.97 | 24.33 | 14.91 |
| PBIT / Share (Rs.) | 25.53 | 30.57 | 26.42 | 13.89 | 5.44 |
| PBT / Share (Rs.) | 24.57 | 29.37 | 25.19 | 12.91 | 3.74 |
| Net Profit / Share (Rs.) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| NP After MI And SOA / Share (Rs.) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| PBDIT Margin (%) | 28.52 | 30.91 | 29.37 | 25.52 | 18.24 |
| PBIT Margin (%) | 17.78 | 21.25 | 20.98 | 14.57 | 6.65 |
| PBT Margin (%) | 17.11 | 20.42 | 20.01 | 13.54 | 4.57 |
| Net Profit Margin (%) | 12.88 | 15.13 | 14.85 | 10.16 | 3.78 |
| NP After MI And SOA Margin (%) | 12.88 | 15.13 | 14.85 | 10.16 | 3.78 |
| Return on Networth / Equity (%) | 12.82 | 17.09 | 17.66 | 11.01 | 3.95 |
| Return on Capital Employeed (%) | 16.36 | 22.17 | 22.51 | 13.92 | 6.39 |
| Return On Assets (%) | 10.25 | 13.29 | 13.45 | 7.80 | 2.78 |
| Long Term Debt / Equity (X) | 0.02 | 0.03 | 0.05 | 0.07 | 0.03 |
| Total Debt / Equity (X) | 0.06 | 0.05 | 0.08 | 0.11 | 0.13 |
| Asset Turnover Ratio (%) | 0.83 | 0.95 | 0.95 | 0.81 | 0.00 |
| Current Ratio (X) | 2.91 | 2.86 | 2.60 | 2.05 | 1.67 |
| Quick Ratio (X) | 2.46 | 2.46 | 2.24 | 1.78 | 1.37 |
| Dividend Payout Ratio (NP) (%) | 10.79 | 9.17 | 10.69 | 0.00 | 64.60 |
| Dividend Payout Ratio (CP) (%) | 5.88 | 5.60 | 6.83 | 0.00 | 15.91 |
| Earning Retention Ratio (%) | 89.21 | 90.83 | 89.31 | 0.00 | 35.40 |
| Cash Earning Retention Ratio (%) | 94.12 | 94.40 | 93.17 | 0.00 | 84.09 |
| Interest Coverage Ratio (X) | 42.79 | 37.19 | 54.56 | 24.81 | 8.76 |
| Interest Coverage Ratio (Post Tax) (X) | 20.33 | 19.21 | 29.41 | 10.87 | 2.82 |
| Enterprise Value (Cr.) | 979.08 | 670.65 | 704.61 | 372.30 | 147.42 |
| EV / Net Operating Revenue (X) | 3.08 | 2.11 | 2.53 | 1.77 | 0.81 |
| EV / EBITDA (X) | 10.78 | 6.82 | 8.62 | 6.92 | 4.47 |
| MarketCap / Net Operating Revenue (X) | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| Retention Ratios (%) | 89.20 | 90.82 | 89.30 | 0.00 | 35.39 |
| Price / BV (X) | 3.08 | 2.47 | 2.98 | 1.83 | 0.75 |
| Price / Net Operating Revenue (X) | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| EarningsYield | 0.04 | 0.06 | 0.05 | 0.06 | 0.05 |
After reviewing the key financial ratios for Vimta Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 18.51. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.51, marking a decrease of 3.26.
- For Diluted EPS (Rs.), as of Mar 24, the value is 18.24. This value is within the healthy range. It has decreased from 21.35 (Mar 23) to 18.24, marking a decrease of 3.11.
- For Cash EPS (Rs.), as of Mar 24, the value is 33.92. This value is within the healthy range. It has decreased from 35.65 (Mar 23) to 33.92, marking a decrease of 1.73.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 143.55. It has decreased from 143.78 (Mar 23) to 143.55, marking a decrease of 0.23.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 40.96. This value is within the healthy range. It has decreased from 44.44 (Mar 23) to 40.96, marking a decrease of 3.48.
- For PBIT / Share (Rs.), as of Mar 24, the value is 25.53. This value is within the healthy range. It has decreased from 30.57 (Mar 23) to 25.53, marking a decrease of 5.04.
- For PBT / Share (Rs.), as of Mar 24, the value is 24.57. This value is within the healthy range. It has decreased from 29.37 (Mar 23) to 24.57, marking a decrease of 4.80.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
- For PBDIT Margin (%), as of Mar 24, the value is 28.52. This value is within the healthy range. It has decreased from 30.91 (Mar 23) to 28.52, marking a decrease of 2.39.
- For PBIT Margin (%), as of Mar 24, the value is 17.78. This value is within the healthy range. It has decreased from 21.25 (Mar 23) to 17.78, marking a decrease of 3.47.
- For PBT Margin (%), as of Mar 24, the value is 17.11. This value is within the healthy range. It has decreased from 20.42 (Mar 23) to 17.11, marking a decrease of 3.31.
- For Net Profit Margin (%), as of Mar 24, the value is 12.88. This value exceeds the healthy maximum of 10. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.88. This value is within the healthy range. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
- For Return on Networth / Equity (%), as of Mar 24, the value is 12.82. This value is below the healthy minimum of 15. It has decreased from 17.09 (Mar 23) to 12.82, marking a decrease of 4.27.
- For Return on Capital Employeed (%), as of Mar 24, the value is 16.36. This value is within the healthy range. It has decreased from 22.17 (Mar 23) to 16.36, marking a decrease of 5.81.
- For Return On Assets (%), as of Mar 24, the value is 10.25. This value is within the healthy range. It has decreased from 13.29 (Mar 23) to 10.25, marking a decrease of 3.04.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.83. It has decreased from 0.95 (Mar 23) to 0.83, marking a decrease of 0.12.
- For Current Ratio (X), as of Mar 24, the value is 2.91. This value is within the healthy range. It has increased from 2.86 (Mar 23) to 2.91, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 24, the value is 2.46. This value exceeds the healthy maximum of 2. There is no change compared to the previous period (Mar 23) which recorded 2.46.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 10.79. This value is below the healthy minimum of 20. It has increased from 9.17 (Mar 23) to 10.79, marking an increase of 1.62.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.88. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 23) to 5.88, marking an increase of 0.28.
- For Earning Retention Ratio (%), as of Mar 24, the value is 89.21. This value exceeds the healthy maximum of 70. It has decreased from 90.83 (Mar 23) to 89.21, marking a decrease of 1.62.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.12. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 23) to 94.12, marking a decrease of 0.28.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 42.79. This value is within the healthy range. It has increased from 37.19 (Mar 23) to 42.79, marking an increase of 5.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 20.33. This value is within the healthy range. It has increased from 19.21 (Mar 23) to 20.33, marking an increase of 1.12.
- For Enterprise Value (Cr.), as of Mar 24, the value is 979.08. It has increased from 670.65 (Mar 23) to 979.08, marking an increase of 308.43.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.11 (Mar 23) to 3.08, marking an increase of 0.97.
- For EV / EBITDA (X), as of Mar 24, the value is 10.78. This value is within the healthy range. It has increased from 6.82 (Mar 23) to 10.78, marking an increase of 3.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
- For Retention Ratios (%), as of Mar 24, the value is 89.20. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 23) to 89.20, marking a decrease of 1.62.
- For Price / BV (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 23) to 3.08, marking an increase of 0.61.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
- For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 23) to 0.04, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vimta Labs Ltd:
- Net Profit Margin: 12.88%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.36% (Industry Average ROCE: 17.2%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.82% (Industry Average ROE: 13.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 20.33
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 35.8 (Industry average Stock P/E: 41.75)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.88%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Plot Nos. 141/2 & 142, Hyderabad Telangana 500051 | shares@vimta.com http://www.vimta.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Sivalinga Prasad Vasireddi | Executive Chairman |
| Ms. Harita Vasireddi | Managing Director |
| Mr. Harriman Vungal | Executive Director - Operations |
| Mr. Satya Sreenivas Neerukonda | Executive Director |
| Dr. Yadagiri R Pendri | Independent Director |
| Ms. Prameela Rani Yalamanchili | Independent Director |
| Mr. Sanjay Dave | Independent Director |
| Mr. Purnachandra Rao Gutta | Independent Director |
FAQ
What is the intrinsic value of Vimta Labs Ltd?
Vimta Labs Ltd's intrinsic value (as of 09 December 2025) is 520.38 which is 12.98% lower the current market price of 598.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,673 Cr. market cap, FY2025-2026 high/low of 903/372, reserves of ₹407 Cr, and liabilities of 518 Cr.
What is the Market Cap of Vimta Labs Ltd?
The Market Cap of Vimta Labs Ltd is 2,673 Cr..
What is the current Stock Price of Vimta Labs Ltd as on 09 December 2025?
The current stock price of Vimta Labs Ltd as on 09 December 2025 is 598.
What is the High / Low of Vimta Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vimta Labs Ltd stocks is 903/372.
What is the Stock P/E of Vimta Labs Ltd?
The Stock P/E of Vimta Labs Ltd is 35.8.
What is the Book Value of Vimta Labs Ltd?
The Book Value of Vimta Labs Ltd is 93.5.
What is the Dividend Yield of Vimta Labs Ltd?
The Dividend Yield of Vimta Labs Ltd is 0.17 %.
What is the ROCE of Vimta Labs Ltd?
The ROCE of Vimta Labs Ltd is 25.2 %.
What is the ROE of Vimta Labs Ltd?
The ROE of Vimta Labs Ltd is 19.4 %.
What is the Face Value of Vimta Labs Ltd?
The Face Value of Vimta Labs Ltd is 2.00.